One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
Financial Toxicity in Cancer Clinical Trials: An Issue in Need of Clarity and Solutions.
doi : 10.1200/JCO-24-01577
Volume 43(20) pgs. 2231-2337 July 10, 2025
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE.
doi : 10.1200/JCO-24-02818
Use of Low-Value Cancer Treatments in Medicare Advantage Versus Traditional Medicare.
doi : 10.1200/JCO-24-01907
PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma.
doi : 10.1200/JCO-24-02210
Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma.
doi : 10.1200/JCO-24-02158
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Mantle Cell Lymphoma.
doi : 10.1200/JCO-25-00568
Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase-Targeted Approaches.
doi : 10.1200/JCO-25-00146
